Share This Page
Drug Sales Trends for BRINTELLIX
✉ Email this page to a colleague


Annual Sales Revenues and Units Sold for BRINTELLIX
Drug Name | Revenues (USD) | Units | Year |
---|---|---|---|
BRINTELLIX | ⤷ Try for Free | ⤷ Try for Free | 2021 |
BRINTELLIX | ⤷ Try for Free | ⤷ Try for Free | 2020 |
BRINTELLIX | ⤷ Try for Free | ⤷ Try for Free | 2019 |
>Drug Name | >Revenues (USD) | >Units | >Year |
Market Analysis and Sales Projections for Brintellix (Vortioxetine)
Introduction to Brintellix
Brintellix, known as Trintellix in the U.S., is an antidepressant developed by Lundbeck and Takeda Pharmaceutical. It is approved for the treatment of major depressive disorder (MDD) and has been gaining significant traction in the global pharmaceutical market.
Market Performance
Current Market Size and Growth
As of 2024, the global Vortioxetine market size is estimated at USD 915.8 million. This figure is driven by strong demand across various regions, particularly in the U.S., Europe, and International Markets[4].
Regional Breakdown
- North America: The North American market for Vortioxetine accounts for approximately USD 366.32 million in 2024, with a projected Compound Annual Growth Rate (CAGR) of 8.8% from 2024 to 2031[4].
- Europe: Europe's Vortioxetine market is valued at USD 274.74 million in 2024, expected to grow at a CAGR of 9.1% during the same period[4].
- Asia Pacific: This region holds around 23% of the global revenue, with a market size of USD 210.63 million in 2024 and a CAGR of 12.6% from 2024 to 2031. The growth here is influenced by factors such as urbanization, lifestyle changes, and social stress[4].
- Latin America and Middle East & Africa: These regions contribute smaller but significant portions to the global market, with Latin America accounting for USD 45.79 million and the Middle East & Africa accounting for USD 18.32 million in 2024. Both regions are expected to grow at CAGRs of 10% and 10.3%, respectively[4].
Sales Projections
Global Growth
The global Vortioxetine market is projected to expand at a CAGR of 10.60% from 2024 to 2031, reaching USD 1,853.9 million by 2031. This growth is driven by increasing awareness of mental health, technological advancements, and regulatory support[4].
Key Markets
- United States: Brintellix has seen significant growth in the U.S., driven by higher demand and strategic marketing efforts. In the first half of 2024, U.S. sales contributed substantially to Lundbeck's overall revenue, with Brintellix/Trintellix sales growing by 11% in local currencies[1][2].
- Europe: In Europe, Brintellix has also performed well, with sales growth of 16% in local currencies in the second quarter of 2024. Countries like Spain, Italy, and France are among the largest markets for the drug[1].
- International Markets: Outside the U.S. and Europe, Brintellix has seen strong uptake, particularly in Canada, Brazil, and Japan. These markets have contributed to the overall growth of the product, with sales increasing by 13% in local currencies in 2024[1][5].
Market Drivers
Increasing Demand for Antidepressants
The growing prevalence of depression and anxiety, coupled with increasing awareness and public campaigns promoting mental health, has driven the demand for effective antidepressants like Brintellix[4].
Differentiation and Efficacy
Brintellix is distinguished by its positive effects on cognition and a reasonably tolerable side effect profile, making it a preferred option for patients, especially the elderly and those who fail to respond to generic SSRIs[3].
Regulatory Support
Regulatory assistance and approvals in various regions have facilitated the market penetration and growth of Brintellix. For instance, the drug's approval for the treatment of MDD has been instrumental in its success[4].
Market Challenges
Generic Competition
The antidepressant market faces significant generic competition, which can erode the sales of branded drugs. However, Brintellix's unique profile and efficacy have helped it maintain market share despite this competition[3].
Economic Factors
Economic factors such as pricing pressures and healthcare budget constraints can impact the sales of Brintellix. However, the drug's strong performance in key markets has mitigated some of these effects[1][2].
Strategic Brands Performance
Lundbeck's strategic brands, including Brintellix, have been the driving force behind the company's revenue growth. In the first half of 2024, these brands reached DKK 4,737 million, increasing by 20% in local currencies, with Brintellix contributing significantly to this growth[1].
Quotes from Industry Experts
"Brintellix is expected to be one of the most successful new agents in the unipolar depression markets... because of its potential for positive effects on cognition and its reasonably tolerable side effect profile," said Alana Simorellis, senior business insights analyst at Decision Resources[3].
Illustrative Statistics
- Global Market Size: USD 915.8 million in 2024[4].
- Projected Growth: USD 1,853.9 million by 2031[4].
- CAGR: 10.60% from 2024 to 2031[4].
- U.S. Sales Growth: 11% in local currencies in the first half of 2024[1].
- European Sales Growth: 16% in local currencies in the second quarter of 2024[1].
Key Takeaways
- Brintellix is a significant player in the global antidepressant market, driven by its efficacy and tolerable side effect profile.
- The drug has seen strong growth in key markets such as the U.S., Europe, and International Markets.
- The global Vortioxetine market is projected to grow at a CAGR of 10.60% from 2024 to 2031.
- Increasing awareness of mental health and regulatory support are key drivers of the market.
- Despite generic competition, Brintellix's unique profile has helped it maintain market share.
FAQs
What is Brintellix used for?
Brintellix, known as Trintellix in the U.S., is used for the treatment of major depressive disorder (MDD)[1][3].
What are the key markets for Brintellix?
The key markets for Brintellix include the U.S., Canada, Spain, Italy, and Japan[1][5].
How is the global Vortioxetine market expected to grow?
The global Vortioxetine market is expected to grow at a CAGR of 10.60% from 2024 to 2031, reaching USD 1,853.9 million by 2031[4].
What differentiates Brintellix from other antidepressants?
Brintellix is differentiated by its positive effects on cognition and a reasonably tolerable side effect profile, making it a preferred option for patients[3].
How has Brintellix performed in recent years?
Brintellix has seen significant growth in recent years, with sales increasing by 11% in local currencies in the U.S. and 16% in Europe in the second quarter of 2024[1].
Sources
- Lundbeck Q2 2024 Financial Report: Lundbeck, August 2024.
- Lundbeck Keeps Turnaround Coming in H1: FiercePharma, August 2016.
- Antidepressant Brintellix Tipped as Blockbuster: PharmaTimes, August 2013.
- Global Vortioxetine Market Report: Cognitive Market Research, July 2024.
- Lundbeck Delivers Record Revenue: Lundbeck, February 2023.
More… ↓